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ABSTRACT
Innovation and firm creation are enablers of industry development, 
especially in industries that are technology-intensive. In the 
contexts of an emerging industry, industry development supports 
the transformation of an emerging economy into a developed one. 
Therefore, by understanding innovation and firm creation strategies 
and the variables that influence them entrepreneur-managers will 
be able to design strategies for the development of their firms, and 
policy makers will be able to institute a conducive environment 
which support rapid growth of the industry. This study examines the 
strategies for innovation and firm creation adopted by 92 companies 
in the emerging Malaysian biotechnology sector. The objective is to 
gain an understanding of the variables that influence their innovation 
and firm creation strategies. To achieve this objective, content analysis 
methodology was utilized and data was gathered from sources in 
the public domain. Findings reveal industry’s contextual variables 
influence innovation and firm creation in the emerging biotechnology 
industry. Some of the emergent strategies for companies in this industry 
are establishing a family of firms, collaborating with business partners, 
locating their operation close to resources, and internationalizing their 
operation. These strategies, in turn, are influenced by the age and size 
of the companies. These findings can be explained by three major 
theories of competition; the influence of the external environment 
can be explained via the industrial organization perspective, while 
the resources and innovative conduct, being of strategic imperatives 
can be described through the resource-based and the Schumpeterian 
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views. These insights offer entrepreneur-managers and policy 
makers directions toward enhancing the process of innovation and 
firm development, which in turn can support the development of 
technology-intensive companies and industries. 
Keywords: Innovation, firm creation, strategic management, 
biotechnology, technology-intensive industry, emerging economy
INTRODUCTION
Biotechnology, as defined in this study, is any technological application that 
uses biological systems, living organisms, and/or their derivatives, to develop 
new products and/or to improve on existing products or processes. It has diverse 
applications in agriculture, healthcare and industrial processes, products and services 
(BiotechCorp, 2009a:8). The field of biotechnology also includes development of 
processes and methods in related fields or domains, such as those that contribute 
to the development of bioinformatics. Biotechnology is one of the most important 
innovations today; among others, biotechnology innovation helps to advance food 
and medical technologies and thus contributes to the progression in the health and 
well-being of society. Therefore, the development of innovations in the field of 
biotechnology has a very high potential of contributing toward the sustainability 
and well-being of the world, and the economic development of a location or region. 
Theories of economic development and strategic management emphasize that 
development of an industry is supported by the growth of firms within it. In turn, 
the growth of these firms is determined by how well they innovate and what  types 
of innovation they make. In fact, one important assumption in relation to this is that 
innovating is equated with strategizing. This perspective stresses the significance of 
innovation not only in making profits for firms in a particular industry, but also in 
sustaining the whole industry in the long-run. This is because a firm’s profitability 
contributes to its growth, which in turn helps promote industry development, which 
then encourages economic development of a society.  Thus, a firm’s innovativeness 
benefits the firm and consumers, as well as the society at large (Jacobson, 1992; 
Schumpeter, 1934; 1942). 
The above discussion highlights innovation and firm creation as constructs that 
influence industry development. Indeed, industry development is crucial in emerging 
economies such as Malaysia. Malaysia’s biotechnology industry has been designated 
as one of the catalysts for Malaysia’s goal to achieve its developed country status 
in 2020. The government had committed about USD500 million to promote the 
overall biotechnology industry development policy, which was launched in April 
2005 with the goal of developing the biotechnology industry into one that would 
350
International Journal of Economics and Management
contribute 2.5% of the Malaysian GDP in the year 2010 (BiotechCorp, 2007). The 
underdeveloped state of this industry indicates that the industry is still in its infancy.
The government’s biotechnology industry goal requires that the infant industry 
be strategically developed and sustained. This, in turn, requires that the firms 
operating in this industry to strategize their efforts toward achieving high growth, 
while policy makers are responsible for designing a support structure that will 
ensure that the industry continues to prosper and bring strategic advantages to the 
country’s economics aims. In promoting the growth of the industry, entrepreneur-
managers need to have knowledge about innovation and firm creation strategies in 
the industry and the variables that influence them; this is to enable them to design 
strategies to develop their firms and support policy makers in instituting a conducive 
environment which will help support a rapid growth of the industry. This study, 
therefore, examines strategies of innovation and the structure of firm creation in 
the Malaysian biotechnology industry. The objective of this study is to generate a 
set of variables that influence strategizing in the industry. 
The  firms chosen for this study were companies with the BioNexus status, a 
status awarded to biotechnology firms that have met the criteria set by BiotechCorp. 
The most important criterion is the ability of the firms to exploit leading-edge 
biotechnologies in the three focus areas (agriculture, healthcare, and industrial) 
of the Biotechnology Policy. The BioNexus Program, which was introduced in 
2006, is a comprehensive support program for biotechnology product and firm 
development. The status provides biotechnology firms access to tax incentives, 
government funding and relevant industry networks (BiotechCorp, 2007). The aim 
of these is to promote rapid growth of the companies and encourage more foreign 
direct investments in the biotechnology industry. BiotechCorp is a government-
based agency established in 2005 as a part of the Malaysian Biotechnology Policy 
initiative to support the industry’s development. The agency operates under the 
Ministry of Finance, and is managed by both the Ministry of Science, Technology 
and Innovation (MOSTI) and the Prime Minister’s Department. It administrates 
the granting of BioNexus status to selected biotechnology firms and the dispensing 
of government incentives, including financial grants.  
In this study, a list of BioNexus companies totalling 92 firms was compiled from 
the BiotechCorp database at the end of 2008. To achieve the study’s objective, we 
included all 92 companies in our analysis, and utilized content analysis methodology 
with data gathered from sources in the public domain. 
The term innovation in this study refers to biotechnological innovation; 
strategies of innovation refer to the company’s products or services, or both, and 
grouped according to the sector in which they were positioned, including agriculture, 
healthcare, and industry. Strategies of innovation also include the types of markets 
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served by the company. Strategies of firm creation, on the other hand, were measured 
by the location of the biotechnology firms and type of organization, either public-
listed or privately-held, and whether they were independent or part of a group of 
companies, as well as the existence of collaborative alliances or partnerships. 
The structure of this study first provides some background information on the 
policies and biotechnology industry in Malaysia. Second, it presents the theoretical 
perspectives on innovation and firm creation strategies and the conceptual 
framework. Third, it describes the research methodology and the data collection 
process. Finally, the study analyzes the findings and discusses its main conclusions. 
BACKGROUND OF THE BIOTECHNOLOGY POLICIES AND 
INDUSTRY IN MALAYSIA
In 2005, the Malaysian government launched the Biotechnology Policy and 
designated the biotechnology industry as a strategic industry; the industry has since 
received a lot of support from the government. The policy reflects a comprehensive 
plan for the industry’s development. Instead of developing Malaysia’s capabilities 
in biotechnology from the basic (as in the case of an earlier Malaysian government 
policy on the development of the ICT and multimedia industry), the biotechnology 
policy fosters the industry’s growth by designating the agriculture, healthcare and 
industrial sectors as focus areas of development. The three sectors were amongst 
the country’s major focus areas of development in the government’s earlier policies. 
In this way, the capabilities in biotechnology can be developed from the existing 
bases, as the three sectors are already established industries. 
Under the Malaysian biotechnology policy, the development of these three 
sectors are directly supported by extensive R&D efforts, human capital, financial, 
and legislative development, which are aligned with market positioning strategies in 
the international markets. These supports are provided mainly through BiotechCorp, 
the central biotechnology industry development agency, with the aid from many 
other agencies (Iskandar Mizal, 2009; BiotechCorp, 2009b; BIOTEK, 2011).
One of the most important mechanisms in promoting the development of 
the biotechnology industry is the BioNexus program, which grants the BioNexus 
status to biotechnology firms that meet the criteria set by the BiotechCorp. The 
BioNexus program enables innovative companies to get tax-deferred advantage, 
receive priority in getting funding from government agencies, and gain access 
to the expertise networks of BiotechCorp (BiotechCorp, 2007). The BioNexus 
programs are supported by a network of about 50 agencies, some of which are 
newly created units, while others are existing agencies with re-focused goals 
to support the implementation of the biotechnology policy (Khairul Akmaliah, 
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Hasmiah, Mohd Fuaad & Igel, 2012). The new agencies include the BiotechCorp 
and InnoBio. The latter is a government entity that provides direct consultancy 
and contract research to client biotechnology organizations. It primarily supports 
firms in the field of biopharmaceuticals, which include research institutes and 
pharmaceutical companies. It also provides training to researchers at universities 
and research institutes to help them keep abreast with the latest technological 
development. InnoBio has also planned to operate an incubation facility to support 
the development of biotechnology firms (InnoBio, 2010). 
Expanding or refocusing the functions of several existing agencies  enables 
the biotechnology policy to ‘piggyback’ on these agencies’ existing structures. 
These agencies include the Technology Park Corporation (TPM)  and Malaysian 
Technology Development Corporation (MTDC). TPM, a science park operator and 
manager, was formed in 1996 in conjunction with the launching of the Multimedia 
Super Corridor (MSC) Program; From 2005, TPM’s roles have been expanded to 
directly support the implementation of the biotechnology policy, including through 
the operation of an incubating facility for biotechnology R&D. Its subsidiary, TPM 
Biotech is directly involved in handling biotechnology R&D and commercialization, 
and providing biotechnology R&D, commercialization, manufacturing, and 
marketing services to client companies that are located within and outside of its park 
(TPM, 2010; TPM Biotech, 2010). Another agency is MTDC, which was formed in 
1992 and its function was strenghtened in 1996 to support the earlier-launched MSC 
Program. However, since 2005 its roles have been expanded to directly support the 
biotechnology policy implementation, through administering three university-based 
incubators, handling the Commercialization of R&D Funds and the Technology 
Acquisition Funds, as well as managing and organizing the Symbiosis Program, 
which is a comprehensive support program for commercialization of universities’ 
intellectual properties (BIOTEK, 2009).
One of the services provided by BiotechCorp is its online portal, called the 
Triple Helix, which acts as a centralized database of R&D output and facilities in 
Malaysia. This portal, which enables the virtual clustering of talent, research and 
industries, is aimed to provide a more efficient exchanges within the biotechnology 
sector, including those of BioNexus firms. More recently, BiotechCorp has expanded 
its role to assist in an infrastructure-based project, called the Bio-Xcell project. 
This project is an effort by the agency to link the development of the biotechnology 
industry to its supporting physical infrastructure, in which established anchor 
companies are invited to set up their operations. The objective is to attract other 
biotechnology firms to locate close to these anchor companies (Bio Xcell, 2010). 
An earlier study found that the Malaysian biotechnology industry has already 
had all the necessary elements that directly support R&D efforts, human capital, 
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financial and legislative developments, as well as market positioning strategies 
in the international markets (Khairul Akmaliah, Hasmiah and Mohd Fuaad, 
2011). For example, a lot of effort has been made to ensure that a steady number 
of biotechnology inventions are produced by local universities. By the end of 
January 2009, 12 public universities had conducted biotechnology research and 
their efforts spanned from agriculture-biotechnology research to DNA recombinant 
exploitation. Five universities, Universiti Kebangsaan Malaysia (UKM), Universiti 
Putra Malaysia (UPM), Universiti Malaya (UM), Universiti Sains Malaysia (USM), 
and Universiti Malaysia Sabah (UMS), had a department or institute dedicated to 
biotechnology research. In the same period, the amount of grants awarded by the 
Malaysian government to these universities for biotechnology research amounted to 
more than USD50 million. Additionally, 14 research institutes had also carried out 
biotechnology research, with 13 of them were government-owned institutes while 
one was a privately operated entity. These research institutes performed researches 
that were more applied in nature compared to university-based researches, which 
were more science-based. The Malaysian government had also provided several 
grant schemes for the commercialization of biotechnology products and services.
The biotechnology policy also has in place several comprehensive programs 
that transcend the usual innovation value chain process and involve many players. 
They include the a) MTDC Symbiosis program, which supports the entire 
spectrum of the innovation process as well as firm development; b) BiotechCorp 
BioNexus Program, which comprises a comprehensive development package for 
biotechnology firms; and c) MOSTI’s grant programs which fund research and 
development (i.e., the Science Fund) and pre-commercialization phase of product 
development (i.e., the Techno Fund). These follow-through efforts are aimed to 
increase the success of support programs for the development of biotechnology 
industry. Within these comprehensive programs, there exist efficient networks 
among the agencies involved in a specific program (for example, UKM and 
MTDC in the Symbiosis program) and among the specific program (for example, 
the MOSTI grant and the BiotechCorp BioNexus program) (Khairul Akmaliah, 
Hasmiah, Mohd Fuaad and Igel, 2012).
THEORETICAL PERSPECTIVES ON INNOVATION AND  
FIRM CREATION STRATEGIES
There are three perspectives for business strategies that support firm growth and 
sustainability; 1) Industrial Organization (I/O) perspective, 2) Resource-Based 
View (RBV), and 3) Austrian School of Strategy or Schumpeterian-Strategy (SS) 
perspective (Barney, 1986). In general, the I/O perspective emphasizes supportive 
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industry structure, the RBV stresses on availability of internal resources, while the 
Schumpeterian perspective focuses on developing innovative products or business 
activities and gaining marketplace advantage for long-term business sustainability 
(Barney, 1986; Jacobson, 1992; Porter, 2008; Grunert & Hildebrandt, 2004). 
Specifically, the I/O perspective proposes that a firm’s strategies for innovation and 
development are shaped by external factors in its environment. In this perspective, 
firms formulate their strategies based on their understanding of external situation 
(i.e. the characteristics of industry structure) (Porter, 2008). This allows firms 
to manipulate the structural elements of their industry to help them develop 
innovation and formulate strategies which will allow them to achieve profitability 
and sustainability in business. In this sense, strategies for innovation and firm 
growth are attempts to modify firms’ own internal processes in response to the 
structures in the industry.
The RBV perspective, on the other hand, believes that the factors influencing 
firms’ ability to make higher profit and perform better are the effective deployment of 
their own internal resources, unique skills, and distinctive competencies. Resources, 
skills and/or competencies are technical know-how, patents, trademarks, firm’s 
reputation, brand awareness, and/or managers’ ability to cooperate, which may 
vary across industries (Barney, 1991; 2001; Chamberlin, 1933). Generally these 
resources must be valuable, inimitable, rare, and organized in ways that can give 
firms competitive advantage over their rivals (Alvarez & Busenitz, 2001; Barney, 
1991; 2001). Firms then need to design strategies that exploit these ‘positive’ 
differences that they have over their rivals. Thus, based on the RBV perspective, 
firms must design strategies for innovation and growth that will allow them to 
exploit their internal resources, skills, and/or capabilities that will give them a 
competitive edge.   
The last perspective, the SS, suggests that industries are either revolutionized 
or incrementally affected by the introduction of new technologies or modifications 
of existing technologies and/or systems (Schumpeter, 1934; 1942). Thus, the SS 
perspective suggests that, firms must have the entrepreneurial and innovativeness 
abilities to support sustainable operations. The SS perspective believes that a market 
is never stable in terms of supply and demand, and that business opportunities 
will always exist when there is a difference between supply and demand. This gap 
causes unfulfilled needs amongst customers (Jacobson, 1992), which then can be 
acted upon by entrepreneurs by introducing new products/services to customers. 
However, although opportunities for business always exist, entrepreneurs must be 
able to recognize them and be able to gather information about them. Therefore, 
in the SS perspective, prior to developing strategies, firms must be able to identify 
new opportunities that exist in the market. At the same time, the strategies that 
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firms plan to adopt must help them to fill this market gap by offering new products/
services (innovation).  
While some authors emphasize the significance of each of these perspectives, 
i.e. the I/O (e.g. Porter 2008), RBV (Chamberlin, 1933; Barney 1991; 2001), and 
Schumpeterian perspectives (Barney, 1986; Jacobson, 1992), some efforts have been 
made to complement these perspectives. For example, Alvarez and Busenitz (2001) 
augment the entrepreneurship theory, which originates from the Schumpeterian-
strategy concept, through the resource-based perspective. Armstrong and Shimizu 
(2007), on the other hand, suggest incorporating industrial elements when examining 
the resources of firms to further refine the conceptualization of firms’ resources. 
Barney (1986) views the I/O and RBV perspectives as complementary, with the 
I/O focusing on elements within firms’ industry, while RBV emphasizes on the 
factors within them when firms decide which resources should be exploited when 
implementing their strategies. Barney (1986) further proposes an integrated view of 
the three perspectives which complement each other. In particular, he emphasizes 
the importance of complementing the three perspectives as firms need to consider 
the structural and the Schumpeterian elements against their internal characteristics 
when formulating and implementing their strategies.  
CONCEPTUAL FRAMEWORK, STUDY CONSTRUCTS AND 
THEIR OPERATIONALIZATION
In the following paragraph, we propose the strategies most likely to be adopted 
by the BioNexus firms in support of their survival and growth, and discuss 
their measures in brief. In regard to the Biotechnology Innovation strategy, its 
implementation is measured in terms of 1) types of innovation, and 2) types of 
market served.  In regard to firm creation strategy, the two variables used to measure 
its operation are 1) location of firms, and 2) form or design of organization 
Biotechnology Innovation Strategy
The classification of innovation strategy into type of biotech innovation and type of 
market served is based on theories of innovation and the three perspectives on firm 
competition, which are the industrial organization (I/O), resource-based (RBV), 
and Schumpeterian (SS).  
Type of Biotechnology Innovation
The types of innovation are related to the output that biotechnology firms offer 
to their potential customers. Innovation theories suggest classifying innovation 
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according to types of innovation based on sectors because of the distinctive 
features across sectors (Malerba, 2002). In this paper, we utilize the sectoral 
biotechnology innovation categorization based the one prepared by the Malaysian 
Biotechnology Corporation (BiotechCorp) (2009b), which include agriculture, 
healthcare or industrial. Agriculture-biotechnology is the use of biotechnology to 
turn agricultural produce into food and agricultural-based products. It also indicates 
the use of biotechnology in any of the value chain of herbal production, from 
seedling up to harvesting, packaging, and distribution points. Animal biotechnology, 
including those involving marine and fresh water organisms, is also classified under 
agriculture-biotechnology. Healthcare-biotechnology refers to the application of 
biotechnology to produce medicine and health-care products. This includes new 
diagnosis and diagnostic tools, therapies, and medicine. Industrial-biotechnology 
involves the utilization of biotechnology to manage the natural environment, 
including the development of new energy sources and other new products that help 
protect the environment from rapid degradation (BiotechCorp, 2009b). 
When deciding on which type of innovation to produce or offer, the decisions 
made by BioNexus firms can be influenced by its external factors (availability 
of raw materials, regulatory requirements, market needs etc.), which means that 
the decision is affected by an externally-driven situation (the I/O perspective). 
Industrial organization perspective describes customers as a sector in its discussion 
on environmental elements.  According to this perspective, the types of innovation 
demanded by customers have an influence on how a strategy is devised by 
management. Therefore based on this deduction, the variable ‘sector’ or ‘type of 
innovation’ is included into the study as it can influence the type of innovation 
strategy utilized by the BioNexus firms.   
The firms’ decision can also be based on the availability of their internal 
resources (technical expertise, availability of equipment, financial strength etc.), 
while having the ability to operate within a selected innovation category points 
to the entrepreneurial capability of their managers. These capabilities indicate 
innovation as an internally-driven action (the RBV perspective). In parallel, having 
the ability to operate within a selected innovation category indicate the adoption of 
both the SS and RBV perspectives by managers and leaders of the BioNexus firms. 
Data on types of innovation were gathered from the BiotechCorp internal 
reports. However, while the categorization is based on companies’ core innovation, 
it is possible that some companies are involved in more than one type of innovation 
(BiotechCorp, 2010a). Another categorization of biotechnology innovation is based 
on whether a firm’s innovation is a product or a service, or both. 
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Type of Market Served
Type of market is categorized into local and foreign, or both.  Using this variable, we 
can determine if an innovation produced by a firm is meant for domestic customers 
or exclusively for foreign customers, or both, as this reflects the extent of the firm’s 
value chain operation and its innovation strategy. 
The type of market chosen by a firm can be influenced by external issues 
(customers’ requests, rivals’ actions, government’s regulations etc.) and so it is an 
externally-driven decision (the I/O perspective); on the other hand, if the decision 
is influenced mainly by the firm’s internal situation (shareholders’ request, output 
capacity issue etc.), it is an internally-driven action (the RBV perspective). Having 
the ability to be positioned in a more competitive international market, which 
requires innovative strategizing and relevant resources, indicates the adoption of 
both the SS and RBV perspectives by managers and leaders of the BioNexus firms. 
Firm Creation Strategy
Location of a Firm
Location of a firm refers to the proximity of a firm to its suppliers and other 
relevant companies/agencies (Hall and Bagchi-Sen, 2002; Porter, 1998). This 
study examines the location of BioNexus firms by classifying them into regions 
to enable the analysis of the agglomeration and clustering of the BioNexus firms. 
Selecting a business location can be an externally driven issue; for example, a 
firm might choose its business location by imitating the decision made by its rival 
(the I/O perspective). It can also be an internally-focused matter when the decision 
is based on the firm’s own operational needs and innovative decisions (the RBV 
and the SS perspectives), such as locating close to its suppliers in order to gain 
effective and efficient access to the resources of its suppliers. 
Form or Design of Organization
In the I/O perspective, a firm’s structure is influenced mainly by its external 
situation, while in the RBV and the SS perspective, a firm’s structure is built around 
the efficient and effective use of its resources. By analyzing its form or design, 
we are able to determine the influential factors and the types of resources that a 
biotechnology firm can access efficiently and effectively. 
In this study, form or design is measured using three variables: a) Listed or 
non-listed (which points to whether a firm is a public or privately owned, which 
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also indicates the financial resources of the firm, whether it is obtained from the 
public or others); b) Group or independent (which indicates if a firm is a part of 
a conglomerate or a single independent firm and if the resources of the firm are 
provided by its parent/system companies or mainly gathered from its external 
environment); and c) Existence of alliances or collaborations (which indicates 
the level of support a firm receives from universities, research institutes or other 
commercial entities). 
RESEARCH METHODOLOGY
We employed the content analysis methodology, an empirical technique that can 
be used to analyze numerous volumes of textual data with the aim of gaining 
an in-depth understanding of a phenomenon (Krippendorff, 2004; Krippendorff 
and Bock, 2008; Duriau, Reger and Pfarrer, 2007; Stemler, 2001). This method 
is effective when the objective of a study involves improving the understanding 
of existing constructs or the discovery of new constructs. It is also appropriate 
when published information are available and when access to primary data is not 
convenient (Duriau, Reger and Pfarrer, 2007; Stemler, 2001), which was the case 
with our study. Most agencies and biotechnology companies do not give open 
access to primary data through formal organizational channel. 
Based on Krippendorff (1980), Stemler outlines six questions that need to be 
addressed when using the methodology of content analysis. Five of the questions 
are: “1) What data are analyzed? 2) How are they defined? 3) What is the population 
from which the data is obtained? 4) What are the contexts that are relevant to the 
data being analyzed? and 5) What are the boundaries of analysis?” The last question 
will be described at the end in this section. Addressing these questions will help 
ensure a study to have high reliability and validity.  (A similar content analysis 
research design has been adopted in many earlier studies including those related to 
biotechnology industry (for example, Khairul Akmaliah, Hasmiah & Mohd Fuaad, 
2011) as well as telecommunications industry (for example, Mohd Fuaad & Khairul 
Akmaliah, 2010). For these earlier researches, the content analysis research design 
generates understanding of the research phenomena while also allow new constructs 
and relationships to emerge from the empirical data). 
In fulfilling the first five requirements of Krippendorff-Stemler’s, the types of 
data we collected were pre-defined in the proposed conceptual framework. The data 
gathered for our study include those available in the public domain, as well as direct 
communications with the companies. The study was limited to 92 firms that had been 
granted the BioNexus status by BiotechCorp as of December 2008 (BiotechCorp, 
2010a). The data was gathered in four stages, which began in December 2008 and 
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ended in June 2010. This effort involved compiling the list of companies from 
BiotechCorp, and gathering and analyzing data from published sources and direct 
communications with the BioNexus firms when necessary. Appendix 1 gives a 
detailed description of the four major steps in the data gathering process. 
The data generated through the four steps were then analyzed and categorized. 
Verification procedure was not necessary during analysis since all data were 
“factual”, and not perceptual records (which could be the main reason for ambiguity 
in data classification or improper data coding). By selecting factual data, the research 
avoids the challenges associated with data instability due to interpretation issues, 
while also making it possible to reproduce the findings of the study (Stemler, 2001).
With the types of data to be collected being pre-defined (as discussed in the 
conceptual framework section), the content analysis methodology allowed us to 
establish important elements of innovation and firm creation strategies and generate 
emergent variables. Finally, we tackled the last issue in the use of the content 
analysis methodology, i.e., “what is the target of inference?” (Stemler, 2001). This 
was done through corroborating the emergent elements and constructs, as well as 
their relationships with broader theories of firm growth, which enabled verification 
of the emergent conceptualization and strengthened the internal validity of the study. 
FINDINGS
This section presents the findings, based on the objectives of the study: biotechnology 
innovation strategy and firm creation strategy. 
Biotechnology Innovation Strategy 
Types of Innovation
Types of innovation according to sector: Figure 1 shows that, of the 92 BioNexus 
companies, 43% of the innovations is in the healthcare sector while the agriculture 
sector makes 40 per cent of the biotechnology innovations. Seventeen per cent of 
the innovations is made in the industrial technology sector. 
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17%
Healthcare
Agriculture
Industrial
43%
Source: BiotechCorp 2010a
Figure 1 Core innovation categories of BioNexus firms 
Type of innovation according to product or service: Table 1 shows the companies’ 
core innovation and types of company output. The output of the 92 BioNexus firms 
can be categorized into: a) Exclusively products (59 firms or 64%), b) Exclusively 
services (23 firms or 25%), and c) A combination of both products and services (10 
firms or 11%).  Products are defined as tangible outputs while services range from 
contract research to contract manufacturing services. An example of a company 
that provides a combination of product and service is Bioalpha International which 
produces health formulation and extracts as well as provides contract manufacturing 
and product registration services to other companies. 
Table 1 Core innovation and categories of output
Core innovation
Type of company output
Total
Products Services Products and services
Agriculture 29 3 5 37 (40%)
Heathcare 19 16 4 39 (43%)
Industrial 11 4 1 16 (17%)
Total 59 (64%) 23 (25%) 10 (11%) 92 (100%)
Table 2 provides information on the production value chain of the 59 companies 
involved exclusively in the manufacture of products. All 59 companies are 
involved in research and development. This is perhaps due to the effort to meet 
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the requirements for the BioNexus status which, among others, require a strong 
R&D capability. The agriculture sector has the most number of firms involved 
in producing exclusively products, while R&D, manufacturing, and distribution 
are the most common production value chain activities performed by these 59 
BioNexus companies. 
Table 2 Production value chain (for firms involved exclusively in manufacturing 
products) and their core innovations
Value chain
Core innovation
Total
Agriculture Healthcare Industrial
Exclusively R&D 2 1 0 3
R&D, production and trading* 3 3 2 8
R&D, production and 
distribution*
12 7 6 25
R&D and production 10 6 3 19
R&D, production and investment 
holding
1 1 0 2
R&D, production, trading and 
investment holding*
1 0 0 1
R&D, prototyping, production and 
trading*
0 1 0 1
Total 29 19 11 59
Notes: *Trading refers to the firm’s involvement in overseas’ market while distribution indicates 
exclusively local sale and marketing.
For firms that are involved exclusively in providing service (23 firms), the 
types of services they provided appear to be very diverse and range from one or 
two specialized services to a full-range of services. An example of a specialized 
service company is Green World Genetics Sdn Bhd which offers contract research 
and farming services for seed breeding. An example of a firm providing a full-
range service is StemLife Berhad, which offers a comprehensive service of stem 
cell banking, consultancy, and services. Each service company has its own unique 
innovation, although the categories of services that they offer can be similar. For 
example, although many companies are involved in contract research, the types of 
services they provided are diverse. A case in point is the contract research provided 
by CellSafe International Sdn Bhd for stem cells of umbilical cord and peripheral 
blood. These services are completely different from the ones provided by another 
stem cell company, Stempeutics Research Malaysia Sdn Bhd, which focus on bone 
marrow derived mesenchymal stem cells. 
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The value chain of the ten firms involved in both products and services is 
also diverse, with each having its own unique innovation activities. For example, 
for Bioalpha International’s products, the processes include formulation and 
extraction, while activities for its services consist of contract manufacturing and 
product registration. In contrast, InQPharm’s value chain includes developing its 
own brand of healthcare products and providing clinical contract research and 
manufacturing services.
Type of Market Served
In regard to the types of market in which their products are sold, of the 92 firms, 
30% operate exclusively in the local market and 70% of the firms have presence in 
foreign markets. The number of international ventures is likely to be higher if the 
measures also include the activities performed by the BioNexus firms to support 
their parent or sister companies’ internationalization efforts.   
Strategy for Firm Creation
Location of Firms
Table 3 shows that 70% of the firms (64 firms) are located in the Klang Valley. This 
region is an area of 30 by 50 square kilometers with Malaysia’s capital of Kuala 
Lumpur in its center. The location of the remaining 30% BioNexus companies is 
equally spread in the North, South, West, and East Malaysian regions. When these 
regional locations were analyzed against the firms’ core innovation (Column A vs. 
Column B), the healthcare and industrial sectors are found to be located mainly 
in Klang Valley area, while the agriculture sector is more spread out throughout 
the country. 
Form/Design of Organization
Listed or non-listed: Table 4 shows the classifications of the 92 BioNexus 
companies according to the type of company (public-listed or privately-owned) 
and their core innovation categories. As shown in the table, private limited 
companies dominate the biotechnology market, i.e. 98% of the analyzed firms, 
while the remaining 2% are public-listed companies. Table 4 shows that there are 
two exchanges in Malaysia: the Main Market and the ACE Market. Two public 
BioNexus companies are listed in the ACE Market; StemLife Berhad is listed under 
the Trading/Services sector and Malaysian Genomics Resource Centre Berhad is 
listed under the Technology sector.
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Part of a Group of Firms/Private Independent Companies: Of the 92 companies, 44 
(47%) are private independent companies while 48 companies (53%) are members 
of a group of firms. Each of the 48 companies is either a subsidiary company 
(48%), a parent company (6%), a sister company (6%) or both a subsidiary/sister 
firm (40%). 
Table 5 Core innovation and group of firms/independent firm
Group/Independent categories Core innovation Total
Part of a group of firms Agriculture 21
Healthcare 20
Industrial 7
Total 48 (53%)
Private independent firms Agriculture 16
Healthcare 19
Industrial 9
Total 44 (47%)
Table 5 shows the total number of companies that belong to group of firms 
and are purely independent companies based on their core innovation. As shown in 
Table 5, there is very little difference between the group or independent categories 
and the types of core innovation. The 48 companies that are classified as group of 
firms are related to 82 companies. Therefore, the mean for the number of family 
members for the group of firms is 2.7 firms (48 BioNexus firms plus their 82 related 
companies divided by 48). 
Of the 48 BioNexus companies that are owned by a group of firms, 25 are either 
public-listed firms themselves (two firms) or have relations with other public-listed 
companies (23 firms, including three with international public-listed companies), 
while the remaining 23 firms belong to private-held group of firms. 
Within the public-listed companies’ group, the two public-listed BioNexus 
companies are StemLife Berhad, which is a parent company to its member firms, 
and Malaysian Genomics Resource Centre Berhad, which is a subsidiary to one 
of its two family members. Of the 23 BioNexus companies that are related to 
public-listed companies, 21 have public-listed companies as their parents, while 
the remaining two are associated to public-listed companies through public-listed 
ownership of their parents. Seventeen of the 23 companies’ core innovations are 
connected to their public-listed family members’ core businesses, with all 17 either 
directly serving their parent companies (15 firms) or the parent companies of their 
parents’ (2 firms) core businesses. For example, the core activity of ACGT Sdn Bhd 
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is to support the business operation of its parent company, Genting Plantation Sdn 
Bhd, in plantation activities. Two other companies, Carotech Bio-Vites Sdn Bhd 
and Hovid Research Sdn Bhd, conduct R&D to help with the commercialization of 
their group’s oil palm-based products. Therefore, these BioNexus companies form 
an important part of their groups’ value chain. For the remaining six companies, 
their activities are not directly aligned with their public-listed parent companies’ 
businesses; two of these firms are diversification cases, while four are “investments 
of unrelated business” to their parent firms’ operations. The diversification cases are 
a) GranuLab, the parent company of which is Sindora Berhad, a conglomerate that 
is involved in the shipping business, and b) KL Biotech Manufacturing, a subsidiary 
of Malaysia Steel Berhad, the core business of which is steel production. For the 
investment companies, their parents are investment holding companies, and their 
core businesses are not aligned with or directly related to the biotechnology industry. 
In the second group, which comprises of 23 BioNexus companies that belong to 
a group of firms related to private limited firms, their relationship with their families 
of firms can be classified as follows: a) a BioNexus company that acts as a partner in 
the value chain of a group of firms, in which it directly supports the group of firms’ 
product or services value chain. For example, in the case of Furley Bioextracts Sdn 
Bhd, its sister company, Furley Marketing, provides the distribution service to the 
company. In another case, Holista Biotech Sdn Bhd acts as the parent company to 
two other firms, i.e. Alterni, the group’s product direct marketing subsidiary, and 
Tropical Botanics, the group’s R&D unit; b) a BioNexus company that operates as a 
separate company with its own distinguished products and customers. For example, 
Generti Biosystems handles the commercialization of InfoValley’s digital autopsy 
system while its sister company, i-Gene, manages the development of its medical 
kits family of products. Therefore, for companies that are belonged to a group of 
firms, their relationships with other group members can be in the form of directly 
supporting or complementing their parent/family core businesses, or serving as a 
diversifying unit or an investment arm of their parent firm.
When we examined the date the BioNexus companies were established, the 
results showed that there is little difference in the mean time of their incorporation 
between the groups that are belonged to or affiliated with public-listed companies 
and those which are private independent companies. The mean establishment 
year for 25 BioNexus firms which are related to public-listed company is 5.24 
years, while the mean establishment year for 23 BioNexus firms which are related 
to private firms is 5.43 years. However, the mean year of establishment for 44 
BioNexus private independent firms is 3.52 years. The mean age for companies 
that are belonged to group of firms is higher, which implies that the development 
of the group of firms happens over time. When we examined the mean age of the 
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oldest member of the family in the public-listed and privately-held group of firms, 
the result shows that the mean age of former is 29.16 years, while the latter is 
10.58. This indicates that perhaps time is a factor in influencing the types of firm 
established, either public-listed or private. 
Alliances or Collaborations: All 48 BioNexus companies that are part of a group 
of firms have collaborative relationships with research institutes and private 
companies. For example, Holista Biotech Sdn Bhd and InfoValley conduct 
joint research with local and international organizations, research institutes, and 
universities. Holista Biotech has links with many research-based organizations as 
well as related biotechnology services which provide research, manufacturing, and 
marketing support to the company. While most of the firm’s manufacturing partners 
are locals, many of its research partners are foreign institutions or companies 
(Adriana, Khairul Akmaliah, & Mohd Fuaad, 2010). InfoValley group of companies 
has also established networks with R&D institutes in Europe (Khairul Akmaliah 
& Mohd Fuaad, 2008). 
In addition, all 44 privately-owned independent BioNexus firms have 
collaborative relationships with local and international research institutes and other 
private companies, mainly in research. For example, Orchid Life’s product was the 
result of a research initiated by UPM using the university’s facilities and grant in 
collaboration with Genetwister Technology of Netherland. 
DISCUSSION
In general the Malaysian biotechnology industry has a supportive institutional 
context for its development. Among the incentives provided to this industry are 
incentive for research and development, human capital development, financial 
infrastructure, and regulatory development. Since the implementation of the 
biotechnology policy in 2005, the number of BioNexus companies has been 
increasing. Between 2006 and 2007, there were 42 companies; this number 
increased to 92 by December 2008, 126 in September 2009, and 173 in October 
2010 (BiotechCorp, 12 October 2010; BiotechCorp, 2010b). All companies which 
have been awarded with the BiotechCorp BioNexus status are companies involved 
in leading-edge biotechnology. These companies encompass new independent firms 
as well as subsidiaries of large firms. 
Based on the types of innovation developed by these BioNexus firms, a high 
percentage is in agriculture-biotechnology sector. This high number is to be expected 
since Malaysia is rich in agricultural diversity and the country’s core economic 
focus in agriculture prior to the industrialization policy introduced in mid-1970s. 
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Given these situations, there are many agriculture-based companies in Malaysia. 
Therefore, the availability of supplies (i.e. external factors) is the main reason for 
a large number of agriculture-based biotechnology companies being established 
in Malaysia. Nevertheless, given the high-technology nature of the biotechnology 
innovation, internal capabilities are still needed to take advantage of the available 
resources. Given the novelty of the industries in Malaysia, we can assume that 
the involvement of the companies in the industrial and healthcare industries is not 
mainly influenced by these external factors. 
Although these companies are grouped into specific sectors of agriculture, 
healthcare, and industry, the products and services offered are diverse and the 
activities performed in these sectors are product manufacturing or service, or both. 
In addition, while companies in the product category are involved in research and 
development, production or distribution or a combination of them, the activities 
of companies within the services appear to be very diverse. This indicates that 
each industry member has its own innovation, and many of them have a unique 
value chain. This is not surprising as having an innovative product or process is 
one important pre-condition in obtaining the BioNexus status. Therefore these 
companies are often not in direct competition with one another. Moreover, as 
incentives are only given to companies with unique innovations, they are encouraged 
to generate more innovations within the industry. 
In regard to the type of market served by these firms, most of the companies 
serve foreign markets. This indicates high internationalization initiatives and their 
readiness to enter foreign market. It seems that internationalization is pursued to 
meet the global demand for biotechnology products and services, to develop their 
markets, and perhaps also to overcome the challenges relating to underdeveloped 
domestic biotechnology markets. This indicates that the decision on the type of 
market among the BioNexus companies is driven by both internal and external 
considerations. 
Most healthcare and industrial firms are clustered in the Klang Valley area. 
This shows that the Klang Valley offers benefits, particularly for the healthcare 
business. The benefits are in forms of close proximity to highly-skilled workers, 
suppliers, and customers. Thus, it seems that the decision to location is more 
influenced by external factors (i.e. customers’ needs and suppliers’ availability). 
For agricultural-based biotechnology companies, most productions are conducted at 
or near the locations of agriculture estates, farms, or cultivation areas. This means 
that close proximity to ingredient-supplying sites is also an enabler for firms to 
develop their agriculture biotechnology business. Therefore, for this group of firms, 
their locational decision is mainly internally-driven (i.e. production requirements).
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In regard to public-listed versus privately-owned companies, two are listed 
on the ACE Market and another ninety are privately-held firms. The two public-
listed companies belong to a sector category known as Trading/Services and 
Technology, respectively. Neither the main board nor ACE has a specific sector 
for biotechnology. The low number of public-listed biotechnology firms and the 
absence of the biotechnology sector in these exchanges highlight the embryonic 
state of the Malaysian biotechnology industry. 
Half of the BioNexus companies are part of a group of firms, while the other half 
is independent private companies. Among companies that are members of groups 
of firms, 48% are either subsidiaries or associated companies of large public-listed 
companies while the remaining 52% have relations with private-limited companies. 
All these suggest the importance of “groupings” among these companies. For 
members of a group of firms, their relationships with other firms in the group can 
be in the form of direct supporters to or complementary partners in the parent/sister 
company’s businesses. Both indicate high reciprocal relationships between them. 
Companies that belong to groups of firms can also be diversified business units of 
their parent companies. Therefore, a highly reciprocal relationship exists between 
a biotechnology firm’s core innovation and the business of its parent company; 
the biotechnology firm serves as an important resource to its group, and in turn 
the parent or sister companies serve as readied customers, important source of 
fund and know-how, or important partners in the value chain or a combination of 
these. In this regard, companies that belong to a group are either direct supporters 
to or are complementary partners in their family of firms. These findings indicate 
that the formation and groupings of the company is a resourced-based decision. 
In regard to the age of the firms, on average, only companies that are more 
than five years old and/or listed companies operate a family of subsidiaries. This 
incremental development of the group of firms indicates that time is a crucial factor 
in the development of biotechnology businesses. Therefore, for these BioNexus 
firms, time or age of firm determines the form/design for the firm’s creation; in other 
words, time or age and organization form/design are interlinked. This indicates that 
the time and age of firm is related to availability of resources of the firm. 
Moreover, the setting up of biotechnology subsidiaries or sister-units by the 
public-listed and grouped-private companies appears to be a strategy which supports 
the rapid development of their group biotechnology products or services portfolio. 
Alternatively, for some large companies, which are in unrelated industries, such 
as steel and shipping, setting up or diversifying in biotechnology businesses in 
recent years indicate that they are following the worldwide trend of investing into 
biotechnology business. 
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The fact that all BioNexus companies have external collaborations implies that 
collaboration with others is a critical strategy for innovation and firm development. 
Many of them have established research collaborations with public-funded 
universities. Perhaps this strategy is adopted to facilitate their research, as all 
BioNexus firms that are involved in biotechnology products are R&D-intensive 
companies. Collaborations provide important resources and so for these firms, 
the ability to establish collaboration is crucial. For groups of firms, collaborative 
relationship seems to supplement the advantage of “groupings”.  On the other 
hand, for independent private firms, collaborations help overcome the limitation 
of “newness” (which includes lack of resources and established networks) while 
buying time for internalization (the time taken to develop into a group of firms). 
For a new company, initially, lack of technical expertise persuades them to 
collaborate more. However, once the company aged and survived the business, they 
have more “internalized” resources, and be able to vertically integrate, through 
establishing subsidiaries and buying related companies. 
In summary, entering international markets, locating close to resources, 
operating under a group of firms and having external collaborations/alliances are 
some of the strategies implemented by the biotechnology firms to support their 
growth.
CONCLUSIONS
The Malaysian biotechnology industry has received extensive government support 
in innovation and firm development. The government’s policy that requires firms 
to have an innovative product or process as one of the preconditions before 
being granted the BioNexus status not only promotes unique innovation amongst 
industry members but also in a way limits direct competition among them. In this 
regard, an environment that is suitable for cutting-edge innovation and promotes 
the development of unique innovations among the biotechnology businesses also 
helps reduce direct competition within the industry. This shows that industry 
contextual variables act as enablers of innovation and firm creation in the emerging 
biotechnology industry. Moreover, the findings also indicate these firms’ ability 
to exploit institutional opportunities and thus, on the whole, their innovativeness 
reflects the I/O (understanding their industry structure) and the SS perspective 
(ability to exploit their environment) of the entrepreneur-managers of these 
companies. 
Further analysis of the data shows the importance of resources of the firm 
in influencing strategies in innovation and firm creation amongst this group 
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of firms. Organizing family of firms, collaborations, selection of location, and 
internationalization are some of the companies’ responses in designing strategies for 
the growth and development of their firms. These strategies, in turn, are influenced 
by the age and size of companies. These findings, which reflect the influence of 
the availability of internal resources of the firm, in the entrepreneur-managers’ 
responses, can be explained by the RBV theories and the Schumpeterian view. 
Taken together, these managerial responses can be explained by the three generic 
perspectives of strategy and competition, which are I/O, RBV, and Schumpeterian; 
resources being the key aspect of firm innovation and development indicate more 
emphasis on the RBV (availability of resources) and Schumpeterian (ability to be 
resourceful in recognizing and exploiting business opportunities).
The capability to exploit new opportunities being a precondition for 
developing and benefiting from a supportive environment indicate the need for 
the biotechnology firms to have market structural knowledge and capabilities to 
leverage on their situation. This points to the function of managerial capability 
and experiences not only in identifying what competitors are doing, but also in 
continuously gathering overall institutional intelligence in the effort to seek new 
opportunities provided by government-supported programs, as well as those in the 
greater environmental contexts. 
Theoretically, the managerial actions or responses of firms are driven mainly 
by their management experiences, which comprise entrepreneurial cognition 
and affective factors as well as other related capabilities, including accumulated 
managerial knowledge as well as important technological and organizational 
resources (Baron, 2004; 2008; Ward, 2004). Management experience, a theorization 
of managerial capabilities developed by Edith Penrose, is a central concept in 
explaining managerial ability to design strategy for their firms’ growth (Penrose, 
1959; Kor & Mahoney, 2004). The conceptualization of managerial response and 
experience in this study, which built upon Penrose’s management experiences, 
affirms the Schumpeterian view and its proponents’ perspectives, which emphasize 
on entrepreneurial capability as a prerequisite for innovation and firm development 
(Hagedoorn, 1996). It can be expected that the need for managerial experience 
is higher in emerging economies given the underdeveloped nature of both the 
institutions and the supplier and customer groups. 
Based on these findings, entrepreneurs-managers gain insights on the important 
constructs that can improve their responses to institutional factors and challenges, 
while policy makers can use the knowledge to institute necessary policy intervention 
that are in line with industry development objectives. 
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APPENDIX 1
The data collection analysis process in this study involved the following four 
major steps:
Step Activities
Step 1 Gather the list of Malaysian Companies with the BioNexus status from 
BiotechCorp Internal Report 
As of December 2008, BiotechCorp listed the number of the BioNexus 
companies according to their core innovation, i.e. agriculture, healthcare or 
industrial (BiotechCorp, 2010a). 
Step 2 Analyze Companies’ Information Based on Predetermined Study 
Constructs
The profile of BioNexus companies gathered in Step 1 was analyzed based on 
the constructs that were predefined in this study. We scrutinized the content of 
the following sources: 
a) Company website;
b) Profiles of the companies’ obtained from the BiotechCorp database 
(BiotechCorp, 2010a) and BiotechCorp official website (www.biotechcorp.
com.my);
c) Description of the nature of business of each company obtained from 
Companies Commission of Malaysia, which is the registrar of companies; 
d) Companies’ information from other sources on the Internet, including 
their parent and/or sister companies’ website, to establish the companies’ 
activities and products/services and to determine the types and value chain 
of biotechnology product/service innovation, and types of markets and 
customers. This is also to verify whether the companies have a parent and 
sister companies with businesses related to biotechnology;
e) Profiles of the companies obtained from the BioMalaysia website. This 
website provided a list and profile of exhibitors in BioMalaysia 2008, which 
includes biotechnology companies with BioNexus status.
f) Profile of BioNexus companies obtained from BiotechCorp internal 
database.
g) Companies’ information obtained from the Bursa Malaysia’s website (http://
www.bursamalaysia.com) and company annual report for public-listed 
companies. This website provided information on companies listed on its 
two boards: the Main Board and the ACE Market. (As of mid-2009, there 
are only two markets in Bursa Malaysia, with the Main and the Second 
Boards merged as the Main Market while the MESDAQ Market, which is 
an exchange platform for technology-based and high growth companies, 
evolved into the ACE Market, which is an alternative market for emerging 
companies. Information on international stock exchanges was also viewed 
where applicable). 
h) MATRADE and MIDA websites, which provided the list of firms that 
were involved in international markets. Both these agencies are supporting 
agencies for Malaysian firms’ internationalization efforts. 
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Step 3 Gather Information from Other Sources in the Public Domain (if necessary) 
In this step, any relevant data that could not be obtained in Step 2 was 
supplemented with other sources of information available in the public domain. 
Step 4 Gather Information through Telephone Interview (if necessary) 
If the required information could not be obtained via Step 3, the information 
was gathered through telephone inquiries from the respective BioNexus firms.
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